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Abstract: Alzheimer’s disease is characterized histopathologically by deposition of insol-
uble forms of the peptide Aβ and the protein tau in brain. Aβ is the principal component of 
amyloid plaques and tau of neuroﬁ  brillary tangles. Familial cases of AD are associated with 
causal mutations in the gene encoding the amyloid precursor protein, APP, from which the 
amyloidogenic Aβ peptide is derived, and this supports a role for Aβ in disease. Aβ can promote 
tau pathology and at the same time its toxicity is also tau-dependent. Aβ can adopt different 
conformations including soluble oligomers and insoluble ﬁ  brillar species present in plaques. 
We discuss which of these conformations exert toxicity, highlight molecular pathways involved 
and discuss what has been learned by applying functional genomics.
Keywords: amyloid, mitochondria, oligomer, proteomic, tau, transgenic
Incidence of dementia
Alzheimer’s disease (AD) is the most common cause of  dementia, comprising 50%–70% 
of all cases and affecting more than 15 million people worldwide. Frontotemporal 
dementia (FTD), in comparison, is less common but may make up to 50% of dementia 
cases presenting before the age of 60 (Graff-Radford and Woodruff 2007). Dementia is 
deﬁ  ned as the signiﬁ  cant loss of intellectual abilities such as memory functions, severe 
enough to interfere with social or occupational functioning. At present, AD cannot be 
cured which is different from memory dysfunction caused by malnutrition, drug abuse 
or depression where some form of treatment is available (Patel et al 2007).
Neuropathology of AD and FTD
The AD brain is characterized by massive neuronal cell and synapse loss at speciﬁ  c 
predilection sites (Selkoe 2002). The extracellular plaques and the intracellular neuroﬁ  -
brillary tangles are the key histopathological hallmarks of AD. The major proteinaceous 
component of the amyloid plaques is a 40- to 42-amino acid polypeptide termed Aβ 
(Aβ40 and Aβ42), which is derived by proteolytic cleavage from the amyloid precursor 
protein, APP, as part of normal cellular metabolism (Glenner and Wong 1984; Masters 
et al 1985). β-Secretase is the protease that generates the amino terminus of Aβ and 
γ-secretase cleavage at the carboxy-terminus dictates its length. Aβ40 is the most 
common species and Aβ42 is the more ﬁ  brillogenic and neurotoxic species. Recent 
evidence suggests that Aβ40 may prevent Aβ42 from aggregating and forming plaques 
(Yan and Wang 2007). β-Secretase activity has been attributed to a single protein, 
BACE 1 (Vassar et al 1999), whereas γ-secretase activity depends on four components, 
presenilin, nicastrin, APH-1 and PEN-2 forming a proteolytic complex (Edbauer et al 
2003). α-Secretase is involved in the non-amyloidogenic pathway by cleaving APP 
within the Aβ domain, thus precluding Aβ formation (Gotz and Ittner 2008). Which 
higher order forms of Aβ exert toxicity is a matter of debate. The conﬂ  icting data as 
well as putative mechanisms of toxicity are discussed in detail below.Neuropsychiatric Disease and Treatment 2008:4(6) 1034
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The second histopathological hallmark of AD are the 
neuroﬁ  brillary lesions that are found in cell bodies and 
apical dendrites as neuroﬁ  brillary tangles, in distal dendrites 
as neuropil threads, and in the abnormal neurites that are 
associated with some β-amyloid plaques (neuritic plaques). 
Neuroﬁ  brillary tangles are also abundant, in the absence 
of overt plaques, in FTD and other so-called tauopathies 
(Lee et al 2001). The neurofibrillary lesions contain 
aggregates of the microtubule-associated protein tau that 
under physiological conditions is mainly localized to the 
axonal compartment of neurons (Goedert et al 1988). In 
tauopathies such as PSP (Progressive Supranuclear Palsy) 
or CBD (Corticobasal Degeneration), tau also forms aggre-
gates in non-neuronal cells (Gotz 2001), emphasizing the 
important role of glia in disease (Kurosinski and Gotz 2002). 
Tau has an unusually high content of serine and threonine 
residues and many of these are phosphorylated under physi-
ological conditions (Chen et al 2004a). Under pathological 
conditions, tau is hyperphosphorylated, which means that it 
is phosphorylated to a higher degree at physiological sites, 
and at additional “pathological” sites. Phosphorylation tends 
to dissociate tau from microtubules. Tau also undergoes a 
conformational change which likely assists in differential 
phosphorylation (Jicha et al 1997). Both tau and Aβ undergo 
nucleation-dependent ﬁ  bril formation (Harper and Lansbury 
1997). In the course of this process, initially dispersed 
polypeptide chains slowly come together to form a diverse 
array of ﬁ  brillation nuclei that enable the rapid outgrowth into 
higher order assemblies including ﬁ  brils (Hortschansky et al 
2005; Pellarin and Caﬂ  isch 2006; Gotz et al 2008).
Genetics of AD and FTD
In familial AD, autosomal dominant mutations have been 
identiﬁ  ed in three genes: APP and the presenilin 1 (PS1) 
and presenilin 2 (PS2) genes. Together, they account for less 
than 1% of the total number of AD cases (Delacourte et al 
2002). In addition, several susceptibility genes have been 
identiﬁ  ed but only the apolipoprotein E (APOE) gene has 
been unanimously conﬁ  rmed and found to be associated with 
sporadic AD (Rocchi et al 2003). Clinically and histopatho-
logically, early-onset familial AD cannot be discriminated 
from late-onset sporadic AD (Gotz 2001).
Whereas in AD no mutations were found in the MAPT gene 
encoding tau, they were identiﬁ  ed in FTD with Parkinsonism 
linked to chromosome 17 (FTDP-17) (Hutton et al 1998; 
Poorkaj et al 1998; Spillantini et al 1998). This established 
that dysfunction of tau in itself can cause neurodegeneration 
and lead to dementia. The existence of a subgroup of FTD 
with no tau aggregation was enigmatic for some time leading 
to the coining of terms such as ‘dementia lacking distinctive 
histology’. This dementia with tau-negative and ubiquitin-
positive lesions today is termed FTLD-U or FTDU-17 
although this is misleading as it implies that the tau lesions in 
FTDP-17 are ubiquitin-negative which is not the case.
FTDU-17 is caused by loss-of-function mutations in 
the gene encoding progranulin (PGRN), a growth factor 
involved in multiple physiological and pathological processes 
including tumorigenesis (Baker et al 2006; Cruts et al 2006). 
The TAR DNA-binding protein of 43 kDa (TDP-43) is 
a constituent of the ubiquitin-positive inclusions in both 
FTLD-U and sporadic amyotrophic lateral sclerosis (ALS) 
arguing for an overlap in the pathology between these two 
entities (Neumann et al 2006). Similar to tau, in diseased 
brain, TDP-43 becomes hyperphosphorylated, ubiquitinated, 
and carboxy-terminally truncated. Mutations in the gene 
encoding valosin-containing protein cause frontotemporal 
dementia with inclusion body myopathy and Paget disease 
of bone (IBMPFD), a rare, autosomal-dominant disorder. As 
TDP-43, but not valosin-containing protein, is accumulating 
in the ubiquitin-positive inclusions in IBMPFD this would 
argue that valosin-containing protein gene mutations lead to 
a dominant negative loss or alteration of valosin-containing 
protein function culminating in impaired degradation of 
TDP-43. In other words, TDP-43 is a common pathologic 
substrate linking a variety of distinct patterns of FTLD-U 
pathology caused by different genetic alterations (Neumann 
et al 2007).
Clinical features of AD and FTD
AD is characterized by early memory deficits, followed 
by a gradual erosion of other cognitive functions such as 
judgment, verbal ﬂ  uency and orientation. The most severe 
neuropathological changes occur in the hippocampal formation, 
followed by the association cortices and subcortical structures, 
including the amygdala and the nucleus basalis of Meynert 
(Arnold et al 1991). Neurofibrillary tangles develop and 
spread in a predictable manner across the brain providing the 
basis for distinguishing six stages of disease progression: the 
transentorhinal Braak stages I-II represent clinically silent 
cases; the limbic stages III-IV incipient AD; and the neocortical 
stages V-VI fully developed AD. By using phosphorylation-
dependent anti-tau antibodies such as AT8, neuronal changes 
can be visualized well before the actual formation of neuroﬁ  -
brillary tangles (Braak and Braak 1991, 1995).
In contrast to AD, which is characterized predominantly 
by memory loss, FTD is mainly initiated with behavioral Neuropsychiatric Disease and Treatment 2008:4(6) 1035
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impairment. The average age of diagnosis is about 60, which 
is around 10 years before the average sporadic AD patient is 
diagnosed (Snowden et al 2001; Weder et al 2007). Patients 
may have an often asymmetrical atrophy of the frontal 
and temporal cortex. There is evidence that motor neuron 
disease and FTD coexist, and the motor symptoms may 
precede, coincide, or follow the development of cognitive 
and behavioral changes (Graff-Radford and Woodruff 2007). 
In a signiﬁ  cant subset of FTD, late parkinsonism is found 
(Lee et al 2001).
Animal models of AD and FTD
To better understand the role of Aβ and tau in AD and 
related disorders, experimental animal models have been 
developed which reproduce aspects of the neuropathological 
characteristics of these diseases (Gotz et al 2007; Gotz and 
Ittner 2008).
In 1995, Games and coworkers established the ﬁ  rst Aβ 
plaque-forming mouse model by targeting high levels of 
the disease-linked V717F mutant form of APP in brain, 
using the platelet-derived growth factor mini-promoter 
for expression. These PDAPP mice showed many of the 
pathological features of AD, including extensive deposition 
of extracellular amyloid plaques, astrocytosis and neuritic 
dystrophy (Games et al 1995). Similar features were observed 
in a second transgenic model established by Hsiao and 
coworkers by expressing the APPsw mutation inserted into a 
hamster prion protein cosmid vector (Hsiao et al 1996). The 
APP23 strain was established by expressing APPsw under the 
control of the neuronal mThy1.2 promoter, with a seven-fold 
overexpression of APP (Sturchler-Pierrat et al 1997; Stalder 
et al 1999). Subsequently, many more models have been 
developed such as the TgCRND8 or J20 mice (Janus et al 
2000; Mucke et al 2000). These mouse models have been 
instrumental in addressing aspects of Aβ toxicity and testing 
therapies such as vaccination trials (Gotz 2001; Gotz et al 
2004b; Kulic et al 2006).
The ﬁ  rst tau transgenic model was established by us in 
1995, expressing the longest human brain tau isoform, without 
a pathogenic mutation, in mice using the hThy1 promoter 
for neuronal expression (Gotz et al 1995). Despite the lack 
of a neuroﬁ  brillary pathology, these mice modeled aspects 
of human AD, such as the somatodendritic localization of 
hyperphosphorylated tau and, therefore, represented an early 
‘pre-tangle’ phenotype. The subsequent use of stronger 
promoters caused a more pronounced tau phenotype in 
transgenic mice (Ishihara et al 1999; Spittaels et al 1999; 
Probst et al 2000; Gotz and Nitsch 2001). Once the ﬁ  rst 
pathogenic FTDP-17 mutations were identiﬁ  ed in the MAPT 
gene in 1998, several groups expressed them in mice and 
achieved neuroﬁ  brillary tangle formation, both in neurons 
and in glial cells (Gotz and Ittner 2008). We, for example, 
expressed G272V and P301L mutant tau and obtained mice 
with aggregated tau and neuroﬁ  brillary tangles (Gotz et al 
2001a; Gotz et al 2001b; Gotz et al 2001c; Deters et al 2008). 
The P301L tau-expressing pR5 mice showed a behavioural 
impairment in amygdala- and hippocampus-dependent tasks; 
aspects of the behavioral impairment could be correlated 
with the aggregation pattern of the transgene (Pennanen et al 
2004; Pennanen et al 2006). K369I transgenic mice, on the 
other hand, model Parkinsonism in FTD, in parts owing to 
expression of the transgene in the substantia nigra (Ittner 
et al 2008).
Cross-talk between Aβ and tau
The amyloid cascade hypothesis claims, in simplistic terms, 
that in the pathogenic cascade of AD, Aβ is upstream of 
tau (Hardy and Selkoe 2002). To address the interaction 
between Aβ and tau (Gotz et al 2004a), Aβ plaque-forming 
Tg2576 mice were crossed with tangle-forming P301L 
tau-transgenic JNPL3 mice; also, P301L tau transgenic pR5 
mice were intracerebrally injected with ﬁ  brillar preparations 
of Aβ42 (Gotz et al 2001b; Lewis et al 2001). Both strategies 
caused an increased tau phosphorylation at pathological 
epitopes and neuroﬁ  brillary tangle formation, establishing 
a link between Aβ and tau in vivo (Gotz et al 2001b; Lewis 
et al 2001). Similarly, tangle formation was aggravated by 
infusing brain extracts of aged plaque-forming APP23 mice 
intracerebrally in P301L tau transgenic mice or by crossing 
APP23 and P301L tau transgenic mice (Bolmont et al 2007). 
Together, these studies established that Aβ exaggerates a 
pre-existing tau pathology supporting, at least in parts, the 
amyloid cascade hypothesis in mice.
Interestingly, recent evidence suggests that Aβ toxicity 
is also tau-dependent (Roberson et al 2007). Reducing 
endogenous tau levels prevented behavioral deficits as 
assessed in the Morris water maze, without altering Aβ 
levels. This was achieved by crossing plaque-forming APP 
transgenic mice onto hetero- and homozygous tau knockout 
backgrounds (Roberson et al 2007). Tau reduction also 
protected both transgenic and non-transgenic mice against 
pentylenetetrazole (PTZ)-mediated excitotoxicity as shown 
by dramatic changes in seizure severity and latency. We were 
able to reproduce these ﬁ  ndings in a second plaque-forming 
APP transgenic mouse model (Ittner et al submitted). Earlier 
ﬁ  ndings in cultured hippocampal neurons derived from tau Neuropsychiatric Disease and Treatment 2008:4(6) 1036
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knockout and transgenic mice supports the model that tau 
is required for Aβ toxicity (Rapoport et al 2002). Together, 
this suggests that a reduction in tau levels is a potentially 
powerful treatment strategy for AD and other neurological 
conditions that are associated with neurotoxicity. A mecha-
nistic explanation is lacking and therefore the importance of 
this information should encourage more research groups to 
work on the interaction between Aβ and tau.
Functional genomics and Aβ toxicity
An unbiased approach to address the toxicity of tau and Aβ is 
by functional genomics, which encompasses transcriptomic 
and proteomic techniques (Chen et al 2004b; Hoerndli 
et al 2004; David et al 2005a; Hoerndli et al 2005). These 
highlighted a role for oxidative stress (see below) and 
impaired axonal transport in disease (Gotz et al 2006). When 
we analyzed the proteome pattern of total brain from P301L 
tau transgenic pR5 and wild-type mice by proteomics, we 
discovered that it was mainly metabolic related proteins 
including mitochondrial respiratory chain complex 
components, antioxidant enzymes and synaptic proteins that 
were modiﬁ  ed in P301L tau mice. Importantly, mitochondrial 
dysfunction could be functionally validated in the P301L 
tau mice. Furthermore, the reduction in mitochondrial 
complex V levels in the P301L tau mice was also decreased 
in human P301L FTDP-17 brains. Finally, P301L tau 
mitochondria displayed an increased vulnerability towards 
ﬁ  brillar preparations of Aβ42, suggesting a synergistic action 
of tau and Aβ pathology on the mitochondria (David et al 
2005b).
In a follow-up study we investigated the toxicity of 
oligomeric Aβ species that in recent years have been 
suggested to be the main culprit, rather than ﬁ  brillar Aβ 
(Hartley et al 1999; Necula et al 2007). The identity of the 
Aβ toxic species in both AD brains and in experimentally 
generated systems correlates best with the soluble, rather 
than the insoluble ﬁ  brillar forms. However, at present, there 
is little chemical and structural detail at the molecular and 
atomic level about the various aggregates to properly deﬁ  ne 
the toxic species (Cappai and Barnham 2008). Interestingly, 
in cortical brain cells obtained from P301L tau transgenic 
pR5 mice both oligomeric and ﬁ  brillar, but not monomeric 
Aβ42 caused a decreased mitochondrial membrane potential 
(Eckert et al 2008a). This was not observed with cerebellar 
preparations indicating selective vulnerability of cortical 
neurons. Furthermore, we measured reductions in state 
3 respiration, the respiratory control ratio and uncoupled 
respiration when incubating P301L tau mitochondria either 
with oligomeric or ﬁ  brillar preparations of Aβ42. We also 
found that aging speciﬁ  cally increased the sensitivity of 
mitochondria to oligomeric Aβ42 damage indicating that 
while oligomeric and ﬁ  brillar Aβ42 are both toxic, they exert 
different degrees of toxicity in mitochondria from older 
animals (Eckert et al 2008a).
To understand which processes are disrupted by Aβ42 
in the presence of tau aggregates a comparative proteomics 
study was performed in both a cellular and an in vivo system 
(David et al 2006). P301L tau expressing neuroblastoma cells 
were treated with Aβ42 as prior studies had shown that this 
caused tau ﬁ  lament formation (Ferrari et al 2003; Pennanen 
and Gotz 2005). In parallel, the amygdala of P301L tau 
transgenic mice was stereotaxically injected with Aβ42 as this 
causes increased tangle formation (Gotz et al 2001b). When 
the deregulated proteins in the two experimental paradigms 
were classiﬁ  ed, it was found that a signiﬁ  cant fraction of the 
altered proteins belonged to the same functional categories, 
ie, stress response and metabolism. We also identified 
model-speciﬁ  c effects of Aβ42 treatment such as differences 
in cell signaling proteins in the cellular model and changes 
in cytoskeletal and synapse proteins in the amygdala. By 
Western blotting and immunohistochemistry, we were able 
to show that 72% of the tested candidates were altered in 
human AD brain with a major emphasis on stress-related 
unfolded protein responsive candidates. This highlights 
these processes as important initiators in the Aβ42-mediated 
pathogenic cascade in AD and further supports the role of 
unfolded proteins in the course of AD (David et al 2006).
Human SH-SY5Y neuroblastoma cells were also 
investigated by transcriptomics to assess the role of P301L 
mutant tau expression and treatment with or without Aβ on 
gene regulation. We found that Aβ and P301L tau expression 
independently affected the regulation of genes controlling cell 
proliferation and synaptic elements. Moreover, Aβ and P301L 
tau acted synergistically on cell cycle and DNA damage 
genes, yet inﬂ  uenced speciﬁ  c genes within these categories. 
By using neuronally differentiated P301L tau cells, it was 
shown that Aβ treatment induced an early up-regulation of 
cell cycle control and synaptic genes. Together, the study 
showed that Aβ treatment and human tau over-expression in 
a cell culture model acted synergistically to promote aberrant 
cell cycle re-entry supporting the mitosis failure hypothesis 
in AD (Arendt 2003; Hoerndli et al 2007).
The Yin and Yang of Aβ
AD has been termed a synaptic failure (Selkoe 2002). While 
Aβ can kill neurons, it can also act by causing synaptotoxicity Neuropsychiatric Disease and Treatment 2008:4(6) 1037
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which may be more relevant for the earlier stages of AD that 
are best characterized by synaptic loss rather than neuronal 
death. Loss of synaptic terminals or dendritic spines could 
cause the associated decline in cognitive functions that charac-
terizes AD. Whether the neurotoxic and synaptotoxic actions 
of Aβ are separate activities or whether they share common 
mechanisms is not known (Cappai and Barnham 2008).
How cells respond to Aβ varies depending upon 
the concentration of Aβ used, which adds another level 
of complexity. While Aβ peptide added at micromolar 
concentrations to primary neuronal cultures induces cell death 
(Yankner et al 1990), low, subnanomolar concentrations are 
neurotrophic arguing in favor of a physiological function of 
Aβ (Yankner et al 1990). As discussed above, the neurotoxic 
activity of Aβ is dependent upon its aggregation state. When 
Aβ aggregation was induced this increased its neurotoxic 
activity suggesting that the toxic species was associated with 
the formation of ﬁ  brils (Pike et al 1991a; Pike et al 1991b; 
Pike et al 1993). At present, however, there is a major research 
focus on the role of non-ﬁ  brillar soluble Aβ as the toxic 
species in AD (Lambert et al 1998; Walsh et al 2002; Smith 
et al 2007). These species have been given different names, 
including Aβ-derived diffusible ligands (ADDLs) (Lambert 
et al 1998). globulomers (Barghorn et al 2005) and the Aβ star 
species 56 (Aβ*56) (Lesne et al 2006). To assist in identifying 
these species, conformational antibodies have been developed 
that not only stabilize the Aβ protoﬁ  brils but also prevent 
mature amyloid ﬁ  bril formation (Habicht et al 2007).
Aβ can inhibit long-term potentiation (LTP), a model 
system for synaptic strengthening and memory (Lambert 
et al 1998; Walsh et al 2002; Cleary et al 2005; Klyubin et al 
2005; Trommer et al 2005). When cell medium containing 
abundant Aβ monomers and proposed oligomers, but not 
amyloid ﬁ  brils was microinjected into rat brain, this markedly 
inhibits hippocampal long-term potentiation (LTP) (Walsh 
et al 2002). Immunodepletion from the medium of all Aβ 
species completely abrogated this effect. Pretreatment of the 
medium with insulin-degrading enzyme, which degrades Aβ 
monomers but not oligomers, did not prevent the inhibition 
of LTP, indicating a role for Aβ oligomers. These were 
shown to disrupt synaptic plasticity in vivo at concentrations 
found in human brain and cerebrospinal ﬂ  uid, in the absence 
of monomeric or ﬁ  brillar amyloid. When cells were treated 
with γ-secretase inhibitors at doses which prevented oligomer 
formation but allowed appreciable monomer production, 
this no longer disrupted LTP, indicating that synaptotoxic 
Aβ oligomers can be targeted therapeutically (Walsh et al 
2002; Walsh et al 2005).
In Neuro-2A cells, oligomers were shown to induce a 
tenfold greater increase in neurotoxicity as compared to 
ﬁ  brils (Stine et al 2003). However, whereas LTP seems to 
be inhibited by oligomeric Aβ only and not ﬁ  brillar Aβ, in 
a different experimental paradigm, the two species seem 
to have both toxic, yet diverse effects (White et al 2005). 
Using rat astrocyte cultures, oligomeric Aβ42 was shown to 
induce initial high levels of the pro-inﬂ  ammatory molecule 
IL-1β that decreased over time, whereas ﬁ  brillar Aβ caused 
increased levels over time (White et al 2005). It has been 
suggested that their neurotoxic activity is associated with 
dimeric and trimeric species however the exact composition 
of these higher molecular weight Aβ species has not been 
determined (Walsh et al 2002; Cleary et al 2005) and remains 
a crucial point to definitively establish their molecular 
identity. Together, this shows that the relative role of the 
toxicity of monomeric compared to oligomeric compared 
to ﬁ  brillar species is far from being resolved.
Aβ and downstream signaling
What are the down-stream effectors of Aβ toxicity? Aβ 
may act via a plethora of pathways to induce synaptic and 
neuronal degeneration (Small et al 2001). Aβ’s anti-LTP 
activity can be modulated with antagonists to the p38 MAP 
kinase (Wang et al 2004) and the Jun NH2-terminal kinase 
(JNK) pathways (Minogue et al 2003), both of which have 
also been implicated in tau phosphorylation (Kins et al 2001; 
Kins et al 2003). While inhibitors of p38, JNK, GSK-3β and 
phosphatidylinositol 3-kinase showed either no or only minor 
inhibition of Aβ oligomer-mediated cell death in mouse 
hippocampal slices, inhibitors of MAPK kinase kinase, which 
is upstream of the extracellular signal-regulated kinases, 
signiﬁ  cantly inhibited Aβ-mediated neuronal death (Chong 
et al 2006).
Another interesting kinase is the non-receptor tyrosine 
kinase Fyn, as it links Aβ and tau. Fyn is a known interaction 
partner of tau (Lee et al 1998). Furthermore, Fyn is neces-
sary for the toxicity of ADDLs (an oligomeric form of Aβ) 
as Fyn knockout neurons are resistant to ADDL-mediated 
neuronal cell death (Lambert et al 1998). Moreover, Fyn 
knockout mice display reduced synaptotoxicity without 
affecting aberrant sprouting, when crossed with APP trans-
genic mice (Chin et al 2004). Fyn has a role in modulating 
synaptic activity and plasticity, by phosphorylating the 
NMDA receptor (Braithwaite et al 2006). This ﬁ  nding is 
consistent with the fact that Aβ oligomers alter the trans-
port of the NMDA receptor by promoting its endocytosis 
and resulting in decreased NMDA receptor activity both Neuropsychiatric Disease and Treatment 2008:4(6) 1038
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in vitro and in APP transgenic mice (Snyder et al 2005). 
Work in neuronal and astrocyte cultures further suggests that 
Aβ causes Ca2+-dependent oxidative stress by activating an 
astrocytic NADPH oxidase, with neuronal death following 
through a failure of antioxidant support (Abramov et al 2004). 
Together, this suggests a ﬁ  ne-balanced network of molecular 
interactions (Cappai and Barnham 2008).
At present it is not understood whether Aβ acts via a 
receptor or whether membrane binding alone is sufﬁ  cient 
(Cappai and Barnham 2008). If Aβ acts via a receptor, this 
receptor may have speciﬁ  city for Aβ or it may bind proteins 
or peptides with shared amyloid properties. Work in primary 
cortical and hippocampal cultures treated with Aβ and human 
amylin, respectively, indicates that the latter may be the case, 
as rat amylin, which is not amyloidogenic, turns out not to be 
toxic (Lim et al 2008). Membrane interaction of Aβ can occur 
via its hydrophobic carboxy-terminal domain (Bhatia et al 
2000; Ambroggio et al 2005) or by electrostatic interactions 
mediated by the charged amino acids in the amino-terminal 
domain (Lau et al 2006). Aβ may bind to the cell membrane 
forming channels or pores that disrupt ion homeostasis, 
hence leading to neuronal dysfunction (Arispe et al 1993; 
Pollard et al 1995; Holscher 1998; Bhatia et al 2000; Lin et al 
2001). As several molecules associated with disease (such 
as the Prion protein, the British peptide, or human amylin) 
can form soluble oligomers and bind to membranes and 
disrupt ion homeostasis, this may be an inherent property of 
amyloidogenic proteins or peptides (Demuro et al 2005).
Aβ binding proteins
A number of Aβ-binding proteins have been identiﬁ  ed on the 
plasma membrane of neurons and glial cells. These include 
the alpha7 nicotinic acetylcholine receptor, the receptor 
for advanced glycosylation end-products (RAGE), APP 
itself, the NMDA receptor, the P75 neurotrophin receptor 
(P75NTR), the scavenger receptors, CD36 and low-density 
lipoprotein receptor-related protein (LRP) members (Verdier 
et al 2004). RAGE can bind both non-ﬁ  brillar and ﬁ  brillar 
forms of Aβ (Yan et al 1996).Transgenic mice co-expressing 
mutant APP and RAGE revealed an earlier onset of memory 
defects and synaptic dysfunction than single APP transgenic 
mice (Arancio et al 2004). LRP, apoE and the serum protein 
α2-macroglobulin (α2M) probably modulate Aβ toxicity via 
clearance of apoE:Aβ and α2M:Aβ complexes or Aβ alone 
from the brain and hence reduce Aβ levels (Shibata et al 
2000; Deane et al 2004). The addition of an anti-NMDA 
receptor antibody can block Aβ oligomer binding to neurons 
and reduce ROS stimulation in hippocampal cultures (De 
Felice et al 2007) suggesting a direct interaction between 
these two proteins. Alternatively, Aβ may be interacting 
with NMDA receptor via an integrin-mediated effect (Bi 
et al 2002). P75NTR can bind a variety of Aβ oligomeric 
species and modulate Aβ toxicity in a cell type- and P75 
isoform-dependent manner (Coulson 2006; Sotthibundhu 
et al 2008). Full-length P75NTR blocks toxicity of ﬁ  brillar 
and non-ﬁ  brillar Aβ in primary neurons (Zhang et al 2003), 
but promotes toxicity of ﬁ  brillar Aβ in neuroblastoma cells 
(Perini et al 2002).
Aβ may not only bind to the cell surface but also act on 
intracellular organelles such as mitochondria (Lustbader et al 
2004; Caspersen et al 2005; Crouch et al 2005; Devi et al 
2006; Manczak et al 2006) whose function it impairs (Keil 
et al 2004; David et al 2005b; Eckert et al 2008a; Eckert 
et al 2008b). Mitochondrial dysfunction was also linked 
to full-length and carboxy-terminally truncated APP, that 
was shown to accumulate exclusively in the protein import 
channels of mitochondria of human AD, but not age-matched 
control brains (Devi et al 2006). Similarly, accumulation of 
full-length APP in the mitochondrial compartment in a trans-
membrane-arrested form, but not lacking the acidic domain, 
was shown to cause mitochondrial dysfunction and impair 
energy metabolism (Anandatheerthavarada et al 2003). Aβ can 
disrupt mitochondrial cytochrome c oxidase activity (Crouch 
et al 2005; Takuma et al 2005) in a sequence- and conformer-
dependent manner (Crouch et al 2005). The Aβ binding 
protein alcohol dehydrogenase (ABAD) is a short-chain 
alcohol dehydrogenase that binds to Aβ in the mitochondrial 
matrix. This lead to mitochondrial failure via changes in 
mitochondrial membrane permeability and a reduction in the 
activities of enzymes involved in mitochondrial respiration 
(Lustbader et al 2004). ABAD can bind to the oligomeric 
Aβ42 present in the cortical mitochondria of APP transgenic 
mice (Yan et al 2007). Protease sensitivity assays suggest 
that Aβ gains access to the mitochondrial matrix rather than 
simply being adsorbed to the external surface of mitochondria 
(Caspersen et al 2005). The interaction between Aβ and 
the mitochondria may explain how Aβ induces apoptosis 
and caspase activation (Ivins et al 1998; White et al 2001; 
Lustbader et al 2004). Intracellullar Aβ may be derived from 
internalized extracellular Aβ or from intracellularly generated 
Aβ (Casas et al 2004; Gomez-Ramos and Asuncion Moran 
2007; Wegiel et al 2007). The presence of intracellular Aβ 
adds a further level of complexity to the mechanism of Aβ 
toxicity as this enables direct access to organelles that are vital 
for the function and viability of neurons. It is needless to say, 
that this has important implications for treatment strategies.Neuropsychiatric Disease and Treatment 2008:4(6) 1039
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Conclusions
What can be expected in the forthcoming years? Some of the 
current therapeutic trials targeting Aβ may come to fruition 
(Gotz and Ittner 2008). With the advent of new tools it will 
likely become easier to discriminate Aβ conformations and 
hence allow establishing a deﬁ  ned role of speciﬁ  c conformers 
in toxicity (Habicht et al 2007). The mode of Aβ uptake 
and/or binding by neurons and other cell types will be 
elucidated and interacting proteins, both under physiologic 
and pathologic conditions, will be identiﬁ  ed. Finally, how 
Aβ and tau interact and contribute to disease will assist in 
the development of treatment strategies for AD and related 
disorders.
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